tbuckley/cabot-search huggingface dataset:
Abstract 15540: Retinal Vein Occlusion and the Risk of Heart Failure Development: A 12-Year Nationwide Population-Based Study
Authors: Jaewon Oh, Tyler Hyungtaek Rim, Sung Soo Kim, Seok-Min Kang, Sungha Park, Sang-Hak Lee, Donghoon Choi
Journal: Circulation (2015)

Background: Retinopathy implied by microvascular dysfunction was known to be related to the risk of heart failure (HF) development. However, there have been no studies for evaluating the risk of HF following retinal vein occlusion (RVO), another surrogate ophthalmologic parameter for microvascular dysfunction. Methods: National registry data were collected from the Korean National Health Insurance Research Database, comprising 1,025,340 (2.2%) random subjects who were selected from 46,605,433 Korean residents in 2002. The definition of HF development based on diagnostic code. The RVO group was composed of patients with an initial diagnosis of either central or branch RVO between January 2003 and December 2007 (n=1,523). The comparison group was composed of randomly selected patients (five per RVO patient; n=7,620) who were matched to the RVO group according to age, gender, residential area, household income, and year of RVO diagnosis. Each sampled patient was tracked until 2013. Cox proportional hazard regressions were used to calculate the overall survival rate for HF development after adjusting for potential confounders, including hypertension, diabetes mellitus, and chronic kidney disease. Results: HF occurred in 11.6% of the RVO group and in 7.9% of the comparison group, respectively (p&lt;0.001). RVO was significantly associated with an increased risk of HF development after adjusting for confounders (hazard ratio (HR) 1.36, 95% Confidence Interval (CI) 1.16-1.89, p&lt;0.001). Other comorbidities including hypertension (HR=2.08), and chronic renal failure (HR=1.88) were also increased the risk of HF development. From the subgroup analysis by age or gender, RVO was still significantly associated with an increased risk of HF development (HR=1.39 for age &lt; 65 years; HR=1.33 for age ≥65 years; HR=1.45 for men; and HR=1.36 for women). Conclusion: RVO was associated with HF development after adjusting for potential confounders. These findings were limited to Korean population and should be validated by additional observational studies.
Abstract 14123: Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy
Authors: Ana Martinez-Naharrro, Tushar Kotecha, Andrea Baggiano, Michele Boldrini, Tamer Rezk, Daniel S Knight, Richa Manwani, Faye Sharpley, Sajitha Sachchithanantham, Shameem Mahmood, Candida C Quarta, Carol J Whelan, Helen J Lachmann, Ashutosh D Wechalekar, James C Moon, Peter Kellman, Julian D Gillmore, Philip N Hawkins, Marianna Fontana
Journal: Circulation (2018)

Introduction: Cardiac involvement in immunoglobulin light chain amyloidosis (AL) is the major determinant of survival. Cardiac response to chemotherapy is conventionally assessed by serum brain nat...
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection
Authors: Rae Jean Proeschold‐Bell, Donna M. Evon, Jia Yao, Donna Niedzwiecki, Christina Makarushka, Kelly A. Keefe, Ashwin A. Patkar, Paolo Mannelli, James C. Garbutt, John B. Wong, Julius M. Wilder, Santanu K. Datta, Terra Hodge, Susanna Naggie, Michael W. Fried, Andrew J. Muir
Journal: Hepatology (2019)

Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions.A total of 181 patients with HCV and qualifying alcohol screener scores at three liver center settings were randomly assigned to the following: (1) medical provider-delivered Screening, Brief Intervention, and Referral to Treatment (SBIRT), including motivational interviewing counseling and referral out for alcohol treatment (SBIRT-only), or (2) SBIRT plus 6 months of integrated colocated alcohol therapy (SBIRT + Alcohol Treatment). The timeline followback method was used to assess alcohol use at baseline and 3, 6, and 12 months. Coprimary outcomes were alcohol abstinence at 6 months and heavy drinking days between 6 and 12 months. Secondary outcomes included grams of alcohol consumed per week at 6 months. Mean therapy hours across 6 months were 8.8 for SBIRT-only and 10.1 for SBIRT + Alcohol Treatment participants. The proportion of participants exhibiting full alcohol abstinence increased from baseline to 3, 6, and 12 months in both treatment arms, but no significant differences were found between arms (baseline to 6 months, 7.1% to 20.5% for SBIRT-only; 4.2% to 23.3% for SBIRT + Alcohol Treatment; P = 0.70). Proportions of participants with any heavy drinking days decreased in both groups at 6 months but did not significantly differ between the SBIRT-only (87.5% to 26.7%) and SBIRT + Alcohol Treatment (85.7% to 42.1%) arms (P = 0.30). Although both arms reduced average grams of alcohol consumed per week from baseline to 6 and 12 months, between-treatment effects were not significant.Patients with current or prior HCV infection will engage in alcohol treatment when encouraged by liver medical providers. Liver clinics should consider implementing provider-delivered SBIRT and tailored alcohol treatment referrals as part of the standard of care.
The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP).
Authors: Christian Buske, Eva Hoster, Martin Dreyling, Joerg Hasford, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2005)
Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL)
Authors: S Choquet, R Herbrecht, G Socie, AM Stoppa, Peter Vandenberghe, W Feremens, A Fischer, F Morschauser, G Salles, E Vilmer, JL Garnier, A Jaccard, T Lamy, P Lang, Y Lebranchu, F Offner, E Oksenhendler, K Imadalou, S Fafi, A Moreau, Leblond, N Milpied
Journal: Blood (2002)
Mdig promotes oncogenic gene expression through antagonizing repressive histone methylation markers
Authors: Qian Zhang, Chitra Thakur, Yao Fu, Zhuoyue Bi, Priya Wadgaonkar, Liping Xu, Zhipeng Liu, Wanqing Liu, Jian Wang, Benjamin L Kidder, Fei Chen
Journal: Theranostics (2019)

The mineral dust-induced gene (mdig) is overexpressed in a number of human cancers, suggesting critical roles of this gene played on the pathogenesis of cancers. Unlike several other JmjC-domain containing proteins that exhibit histone demethylase activity, it remains enigmatic whether mdig is involved in the demethylation processes of the histone proteins.
Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma
Authors: Wen-Ren Wu, Jen-Tai Lin, Cheng-Tang Pan, Ti-Chun Chan, Chen-Liang Liu, Wen-Jeng Wu, Jim Jinn-Chyuan Sheu, Bi-Wen Yeh, Steven K. Huang, Jheng-Yan Jhung, Meng-Shin Hsiao, Chien-Feng Li, Yow-Ling Shiue
Journal: Theranostics (2019)

Muscle-invasive urinary bladder urothelial carcinoma (UBUC) is a lethal disease for which effective prognostic markers and potential therapy targets are still lacking. Previous array comparative genomic hybridization identified that 3q27 is frequently amplified in muscle-invasive UBUCs, one candidate proto-oncogene, B-cell CLL/lymphoma 6 (BCL6), mapped to this region. We therefore aimed to explore its downstream targets and physiological roles in UBUC progression. Methods: Specimens from UBUC patients, NOD/SCID mice and several UBUC-derived cell lines were used to perform quantitative RT-PCR, fluorescence in situ hybridization immunohistochemistry, xenograft, gene stable overexpression/knockdown and a series of in vitro experiments. Results: Amplification of the BCL6 gene lead to upregulation of BCL6 mRNA and protein levels in a substantial set of advanced UBUCs. High BCL6 protein level significantly predicted poor disease-specific and metastasis-free survivals. Knockdown of the BCL6 gene in J82 cells inhibited tumor growth and enhanced apoptosis in the NOD/SCID xenograft model. In vitro experiments demonstrated that BCL6 inhibited cytostasis, induced cell migration, invasion along with alteration of the expression levels of several related regulators. At molecular level, BCL6 inhibited forkhead box O3 (FOXO3) transcription, subsequent translation and upregulation of phosphorylated/inactive FOXO3 through phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and/or epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase 1/2 (MAP2K1/2) signaling pathway(s). Two BCL6 binding sites on the proximal promoter region of the FOXO3 gene were confirmed. Conclusion: Overexpression of BCL6 served a poor prognostic factor in UBUC patients. In vivo and in vitro studies suggested that BCL6 functions as an oncogene through direct transrepression of the FOXO3 gene, downregulation and phosphorylation of the FOXO3 protein.
Screening JAK2 Exon 12 in JAK2 V617F Negative Patients with Myeloproliferative Disorders Reveals a New Splice Site Mutation
Authors: C. Bento, A. Estevinho, I. Rapado, S. Grande, H. Matos, M. Coucelo, S. Osorio, E. Albizua, R. Molinero, M. Duarte, C. Menezes, J. Kaeda, J. Martinez-Lopes, M. L. Ribeiro
Journal: Blood (2008)
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials
Authors: Tove Hegelund Myrbäck, Susanne Prothon, Karl Edman, Jacob Leander, Mahdi Hashemi, Matthew Dearman, Goran Edenro, Petter Svanberg, Eva-Marie Andersson, Joachim Almquist, Carina Ämmälä, Ramon Hendrickx, Ziad Taib, Kicki A Johansson, Anders R Berggren, Christina M Keen, Ulf G Eriksson, Rainard Fuhr, Björn C L Carlsson
Journal: The Lancet Rheumatology (2019)
EBV-Specific Cytotoxic T Lymphocytes by LMP2a- and EBNA3a-Specific T Cell Receptor Gene Transfer for Adoptive Therapy in EBV-Associated Hodgkin’s Disease and Post-Transplant Lymphoma.
Authors: Tuan D. Nguyen, Haike Gelfort, Kathrin Sebelin-Wulf, Oliver Schmetzer, Wolfgang Uckert, Antonio Pezzutto, Marion Subklewe
Journal: Blood (2007)
Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.
Authors: Andrew M. Evens, Kevin A. David, Irene Helenowski, Sheetal M. Kircher, Lauren Mauro, Alla Gimelfarb, Koen Van Besien, Elise Hattersley, Beverly P Nelson, Jayesh Mehta, Leo I. Gordon, Jamile M. Shammo, Scott E. Smith, Sonali Smith
Journal: Blood (2008)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Authors: Nikolaus B. Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky, Jochen Utikal, Christoffer Gebhardt
Journal: Journal for ImmunoTherapy of Cancer (2019)

Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment-derived protein S100A8/A9 qualifies as prognostic marker for melanoma patients, also in the setting of immunotherapy.S100A8/A9 gene and protein expression were analyzed on melanocytic nevi, primary melanomas and metastases using a cDNA library and three independent tissue-microarrays (TMA). Serum levels of S100A8/A9 were measured using a specific ELISA in two independent cohorts of 354 stage III and stage IV melanoma patients as well as in two independent cohorts of patients treated with the PD-1 antibody pembrolizumab.cDNA analysis revealed an upregulation of S100A8 and S100A9 gene expression in melanoma metastases compared to primary melanomas. Significantly higher numbers of infiltrating S100A8/A9 positive cells were found in tissue samples of metastasizing primary melanomas compared to non-metastasizing melanomas (P < .0001) and in melanomas of short-term survivors compared to long-term survivors (P < .0001). Serum S100A8/A9 levels > 5.5 mg/l were associated with impaired overall survival in two independent cohorts (both P < .0001). Importantly, patients with serum elevated S100A8/A9 treated with pembrolizumab showed significantly impaired survival compared to patients with lower S100A8/A9 levels (cohort 1: P = .0051; cohort 2: P < .0001).The tumor microenvironment-associated protein S100A8/A9 serves as a novel prognostic marker for metastasis and survival of metastatic melanoma patients and predicts response to immunotherapy with pembrolizumab. These data underscore the significance of tumor microenvironment-derived factors as suitable biomarkers for melanoma.
Impact of Prior Invasive Pulmonary Aspergillosis (IPA) on Outcome in Patients Receiving Reduced Intensity Conditioning (RIC) Allogeneic Haematopoietic Stem Cell Transplantation (Allo-SCT).
Authors: Jean El-Cheikh, Ling Wang, Benjamin Esterni, Catherine Faucher, Sabine Furst, Hugues de Lavallade, Pierre Berger, Didier Blaise
Journal: Blood (2008)
Abstract 11408: Impact of Preventable Factors of Heart Failure on One Year Rehospitalization; Insights from the Gulf CARE Study
Authors: Amar M Salam, Kadhim Sulaiman, Jassim Al-Suwaidi, Khalid AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Ahmed Al-Motarreb, Prashanth Panduranga, Husam AlFaleh, Abdelfatah Elasfar, Nooshin Bazargani, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Haitham Amin, Nidal Asaad, Awad Al-Qahtani, Rajvir Singh, Magdi Yacoub
Journal: Circulation (2014)

OBJECTIVES: Heart failure (HF) re-hospitalization results in significant costs to the health care system and to patients’ quality of life and has been signaled as an important quality measure in th...
Болезни гепатобилиарной системы: фокус на рациональную гепатотропную терапию
Authors: A.Yu. Filippova
Journal: GASTROENTEROLOGY (2019)

Статья посвящена обзору данных современной литературы и собственных исследований комбинированного использования урсодезоксихолевой кислоты и аргинина глутамата при патологии гепатобилиарной системы. Болезни гепатобилиарной системы сегодня остаются серьезной социально-экономической проблемой здравоохранения во всем мире. Они занимают значительное место в структуре общесоматической патологии в клинике внутренней медицины. Несмотря на очевидные успехи, достигнутые за последние десятилетия в диагностике и лечении заболеваний гепатобилиарной системы, до сих пор некоторые вопросы окончательно не решены или есть противоречия по поводу их лечения. Известно, что не все гепатотропные препараты соответствуют требованиям к активным компонентам, которые патогенетически влияют на звенья патологических процессов в гепатобилиарном тракте. Обосновать и систематизировать лечение заболеваний гепатобилиарной системы при таком разнообразии причин, вызывающих поражение, довольно трудно. Принципы современной терапии большинства болезней гепатобилиарной системы преду­сматривают назначение комбинаций лекарственных гепатотропных средств. Одними из наиболее рациональных комбинаций фармакологических агентов являются препараты урсодезоксихолевой кислоты и аргинина глутамата. Данные фармакологические средства являются препаратами с наибольшей доказательной базой клинической эффективности, значительно превышающей таковую гепатотропных препаратов других групп.
Trisomy 4, a New Chromosomal Abnormality in Waldenstrom’s Macroglobulinemia.
Authors: C. Terre, F. N. Guyen-Khac, C. Barin, M.J. Moziconacci, V. Eclache, C. Leonard, H. Farhat, A. Bouyon, P. Rousselot, S. Choquet, V. Leblond, S. Castaigne
Journal: Blood (2005)
Abstract 15887: Treatment of Skin Inflammation is Associated With a Reduction in High Risk Coronary Plaque Progression at One-Year Follow-up
Authors: Jonathan H Chung, Amit K Dey, Joshua P Rivers, Aparna Sajja, Agastya D Belur, Aditya Goyal, Aditya A Joshi, Joseph B Lerman, Justin A Rodante, Charlotte L Harrington, Veit Sandfort, Martin P Playford, David A Bluemke, Joel M Gelfand, Marcus Y Chen, Nehal N Mehta
Journal: Circulation (2017)

Introduction: Inflammation is critical for the initiation and progression of atherosclerosis. Psoriasis (PSO), a chronic inflammatory skin disease associated with increased risk of MI, provides a r...
Contrast-enhanced harmonic endoscopic ultrasound-guided drainage of a postoperative pancreatic fistula
Authors: Takashi Tamura, Masayuki Kitano, Manabu Kawai, Masahiro Itonaga, Ken-ichi Okada, Hiroki Yamaue
Journal: Endoscopy (2019)

The effectiveness of endoscopic ultrasound (EUS)-guided drainage of a postoperative pancreatic fistula (POPF) has been reported [1] [2] [3]. It is sometimes difficult to distinguish a POPF from surrounding organs and tissues because echogenicity of necrotic or infected tissue becomes as high as that of surrounding tissue in a POPF. Contrast-enhanced harmonic EUS (CH-EUS) may help to identify the spread of a POPF. Here, we present a video case of CH-EUS-guided drainage of a POPF after pancreaticoduodenectomy.
Increased oxidative stress due to dysfunctional HDL in scavenger receptor BI knockout mice
Authors: Miranda Van Eck, Menno Hoekstra, Reeni B. Hildebrand, Yuemang Yao, Dominique Stengel, Uwe J. Tietge, Ewa Ninio, Theo J. Van Berkel, Domenico Pratico
Journal: Circulation (2006)
Prognostic Impact of the Expression of the TLX1 (HOX11) and TLX3 (HOX11L2) Oncogenes in Adult ALL: Experience of the German Multicenter Acute Lymphoblastic Leukemia (GMALL) Therapy Study Group.
Authors: Ulrike Baak, Thomas Burmeister, Nicola Goekbuget, Stefan Schwartz, Dieter Hoelzer, Eckhard Thiel
Journal: Blood (2004)
The Natural History and Treatment Outcome of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients.
Authors: Constantine S. Tam, Michael J. Keating, Susan O’Brien, Alessandra Ferrajoli, Lynne V. Abruzzo, Susan Lerner, Stefan Faderl, Hagop Kantarjian, William Wierda
Journal: Blood (2007)
From genome‐wide association to biological explanation
Authors: M.A.M. Steensel
Journal: British Journal of Dermatology (2019)

Funding sources: M.A.M.v.S.'s research is supported by the Biomedical Research Council of Singapore, IAF‐PP (Industry Alignment Fund‐Prepositioning Program) H17/01/a0/004 and H17/01/a0/008. Conflicts of interest: None to declare. Acne vulgaris (acne) is the most common disease in the world, but its pathogenesis remains poorly understood. As a consequence, no fundamentally new, effective therapeutic approach has been developed since isotretinoin was introduced in 1982. The molecular mechanisms underlying acne must be better understood to address this issue. Unfortunately, there are no good cellular or animal models of the disease, which means we will have to rely on insights gained from human studies. It is well established that acne has a prominent genetic component.1 The more severe the disease, the stronger its heritability. Accordingly, there exist monogenic disorders that are associated with severe acne.1 Of note, the disease in these monogenic conditions responds to isotretinoin or other standard interventions.2 This observation strongly suggests that the genes responsible have an impact on the biological pathways underpinning acne. However, what those are remains to be determined. One might do so by attempting to define the full landscape of acne genetics. If all the genes associated with the disease are known, key biological pathways might emerge based on common gene functions. This is the premise underlying genome‐wide association studies (GWASs). GWASs examine large numbers (often several thousands) of individuals with a particular trait for genetic variants that are associated with it.3
Balanced Rearrangements of Chromosome 6 in Acute Leukaemia: Clustered Breakpoints in 6q22-q23 and Possible Involvement of c-MYB/AHI1 in a New Recurrent Translocation, t(6;7)(q23;q31).
Authors: Paul B. Sinclair, Christine J. Harrison, Marie Jarosova, Letizia Foroni
Journal: Blood (2004)
An epigenome-wide association study of sex-specific chronological ageing
Authors: Daniel L. McCartney, Futao Zhang, Robert F. Hillary, Qian Zhang, Anna J. Stevenson, Rosie M. Walker, Mairead L. Bermingham, Thibaud Boutin, Stewart W. Morris, Archie Campbell, Alison D. Murray, Heather C. Whalley, David J. Porteous, Caroline Hayward, Kathryn L. Evans, Tamir Chandra, Ian J. Deary, Andrew M. McIntosh, Jian Yang, Peter M. Visscher, Allan F. McRae, Riccardo E. Marioni
Journal: Genome Medicine (2019)

Advanced age is associated with cognitive and physical decline and is a major risk factor for a multitude of disorders. There is also a gap in life expectancy between males and females. DNA methylation differences have been shown to be associated with both age and sex. Here, we investigate age-by-sex differences in blood-based DNA methylation in an unrelated cohort of 2586 individuals between the ages of 18 and 87 years, with replication in a further 4450 individuals between the ages of 18 and 93 years.Linear regression models were applied, with stringent genome-wide significance thresholds (p < 3.6 × 10-8) used in both the discovery and replication data. A second, highly conservative mixed linear model method that better controls the false-positive rate was also applied, using the same genome-wide significance thresholds.Using the linear regression method, 52 autosomal and 597 X-linked CpG sites, mapping to 251 unique genes, replicated with concordant effect size directions in the age-by-sex interaction analysis. The site with the greatest difference mapped to GAGE10, an X-linked gene. Here, DNA methylation levels remained stable across the male adult age range (DNA methylation by age r = 0.02) but decreased across female adult age range (DNA methylation by age r = - 0.61). One site (cg23722529) with a significant age-by-sex interaction also had a quantitative trait locus (rs17321482) that is a genome-wide significant variant for prostate cancer. The mixed linear model method identified 11 CpG sites associated with the age-by-sex interaction.The majority of differences in age-associated DNA methylation trajectories between sexes are present on the X chromosome. Several of these differences occur within genes that have been implicated in sexually dimorphic traits.
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
Authors: Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V Marshall, Catherine Vezina, Alberto Pappo, Theodore W Laetsch, Antonio S Petrilli, Martin Ebinger, Jacek Toporski, Julia Glade-Bender, Wayne Nicholls, Elizabeth Fox, Steven G DuBois, Margaret E Macy, Susan L Cohn, Kumudu Pathiraja, Scott J Diede, Scot Ebbinghaus, Navin Pinto
Journal: The Lancet Oncology (2019)
춘계학술대회 발표 : 포스터 발표 ; 급성 간질환 : 우리나라 원발성 담즙정체성 간경변증 환자들의 예후 및 예후 인자: 단일 센터 경험
Authors: 박은하, 이준혁, 이현정, 최용성, 고광철, 백승운, 유병철
Journal: Clinical and Molecular Hepatology (2006)